LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

TransMedics Group Inc

Gesloten

SectorGezondheidszorg

112.01 6.11

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

103.49

Max

107.63

Belangrijke statistieken

By Trading Economics

Inkomsten

9.2M

35M

Verkoop

14M

157M

K/W

Sectorgemiddelde

57.769

35.733

EPS

0.7

Winstmarge

22.181

Werknemers

728

EBITDA

10M

46M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+36.94% upside

Dividenden

By Dow Jones

Volgende Winsten

27 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

358M

3.9B

Vorige openingsprijs

105.9

Vorige sluitingsprijs

112.01

Nieuwssentiment

By Acuity

50%

50%

173 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

TransMedics Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

20 sep 2024, 03:29 UTC

Top Nieuws

Dow Jones Futures: Meta, Apple, Tesla Lead New Buys In Big Rally. Pay Attention To This Key Shift. -- IBD

Peer Vergelijking

Prijswijziging

TransMedics Group Inc Prognose

Koersdoel

By TipRanks

36.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 142.43 USD  36.94%

Hoogste 170 USD

Laagste 115 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor TransMedics Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technische score

By Trading Central

92.43 / 94.18Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

173 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat